Global Respiratory Diagnostics Market Size Report Segmented by Product/Service (Instruments/Devices, Assays/Reagents, Services, Software), Test Type (Mechanical, Imaging, Molecular), Indication (COPD, Asthma, Tuberculosis), Diagnosis Type (Syndromic, Etiological, Prognosis), End-User & Forecast to 2031

Respiratory Diagnostics refers to the range of tests, tools, and technologies used to detect, monitor, and evaluate diseases affecting the respiratory system, including the lungs, airways, and related structures. Diagnostic methods include laboratory-based assays, molecular diagnostics, imaging, pulmonary function, and point-of-care diagnostics, among others, for diseases like asthma, chronic obstructive pulmonary disease (COPD), tuberculosis, and lung cancer, and others, along with the detection of respiratory infections. These diagnostic methods aid in the early detection and characterization of disease, the selection of treatment options, and the management of disease. All this information is instrumental in the delivery of timely clinical decisions, better patient outcomes, and successful public health surveillance and outbreak response. In general, this represents a broad effort to improve the healthcare throughout the world and across clinical care continuum from both preventive and acute, chronic care pathways.

Increasing prevalence of respiratory diseases to propel market demand

The rise in respiratory diseases worldwide is significantly driving the respiratory diagnostics market as it directly impacts early detection, accurate diagnosis, and ongoing disease monitoring. Chronic respiratory issues like asthma, COPD, and pulmonary fibrosis are increasing around the world due to several factors like an aging population, increasing tobacco use, long-term exposure to air pollution, workplace hazards, and urban population growth. According to WHO, COPD is the fourth leading cause of death worldwide, causing 3.5 million deaths in 2021, approximately 5% of all global deaths; while Asthma affected an estimated 262 million people in 2019 and caused 455 000 deaths. As stated in global health estimates, many respiratory diseases are responsible for a large portion of illness and mortality worldwide, putting significant stress on healthcare systems to improve their capacity and efficiency to provide diagnoses of these diseases.

Additionally, the significant burden created by infectious respiratory diseases such as influenza, pneumonia, tuberculosis, respiratory syncytial virus, and emerging viral disease outbreaks highlights the urgent need to develop reliable and fast diagnostic solutions. Seasonal spikes and periodic epidemics lead to increased testing volume, thus increasing the use of molecular diagnostic tests, rapid antigen tests, and multiplex assays that allow for the simultaneous detection of multiple pathogens. Accurate and early diagnosis of disease is important to help manage care for individual patients and to help with infection control and to surveil and prevent future outbreaks, thus contributing to the importance of respiratory diagnostic testing. As a result of increased prevalence rates of respiratory disease, there is now greater emphasis on prevention, early screening, and early detection of respiratory diseases by clinicians. Many healthcare providers utilize several different diagnostic methods including pulmonary function testing, imaging-based diagnostics, and assay-based biomarkers so that respiratory disorders can be identified earlier when they are more amenable to treatment and less costly for health systems. In addition, diagnostics are no longer confined to the hospital setting, but are now used in outpatient clinics, diagnostic laboratories, and community health facilities.

The increased number of patients with chronic respiratory diseases means that there is a greater demand for long-term disease surveillance, resulting in repeated testing along with an increase in point-of-care and home-based diagnostic solutions. Portable spirometers, peak flow meters, and connected diagnostics platforms all support ongoing disease management and remote patient monitoring, thus further increasing the penetration of the market.

With the increasing prevalence of respiratory diseases, healthcare payers and governments are placing greater focus on respiratory health and directly increasing funding of screening programs, education initiatives, and investment in diagnostics. These combined factors will create an ongoing and increasing demand for advanced, accessible, and easily scalable respiratory diagnostics, thus making disease prevalence the primary driver for the growth of the respiratory diagnostics market.

To learn more about this report, download the PDF brochure

Post-COVID-19 awareness and outbreak preparedness is driving the market growth

COVID-19 awareness and preparedness for potential outbreaks has led to the rapid growth of the respiratory diagnostics market as it has fundamentally transformed the way healthcare systems, governments and populations view the risks associated with respiratory health. Due to the COVID-19 pandemic it became evident that critical gaps exist regarding early detection, testing, and surveillance for respiratory infections thus leading to a worldwide assessment of diagnostic preparedness. Now, the healthcare stakeholders are placing more emphasis on rapidly available, accurate and scalable respiratory diagnostic products to provide routine care and address future outbreaks. Among the most important things COVID-19 has done is make large-scale respiratory testing commonplace. The volume of respiratory testing conducted during the pandemic helped promote the adoption of new molecular diagnostics, point of care platforms and rapid antigen tests. Additionally, the expanded testing infrastructure, built to accommodate testing during the COVID-19 pandemic will also continue to be used in the future to provide rapid diagnostics for other respiratory pathogens like influenza, RSV and tuberculosis thereby creating an ongoing demand for diagnostic assays, instruments, and consumables.

Since the coronavirus pandemic, there has been an increased focus by health care providers on identifying respiratory disease pathogens as quickly as possible so that an individual may receive appropriate treatment, determine whether a person with respiratory pathogens should be isolated, and to prevent hospital-acquired infections (HAI) due to these pathogens. This has led to an increase in the use of multiplex and syndromic testing panels to identify multiple respiratory disease pathogens from one specimen, thus improving clinical efficacy and readiness to respond to outbreaks. Market growth has been bolstered by government and public health investment in the establishment of enhanced surveillance systems, the enhancement of laboratory capacity, and the stockpiling of respiratory disease diagnostic kits as part of national preparedness plans for pandemics. Many countries now maintain a strategic reserve of respiratory disease diagnostic tests along with a commitment to uphold many decentralized testing procedures that allow for the rapid distribution of tests in response to future outbreaks. Collectively, these acts create a continual need for respiratory disease diagnostic testing beyond outbreaks.

In addition, public awareness and behavioral changes persist beyond COVID-19. Individuals are more apt to seek out testing for reasonable respiratory symptoms; thus, increasing the volume of routine respiratory disease diagnostic tests throughout outpatient and community settings. As such, employers, schools, and travel authorities will continue to rely on respiratory disease diagnostic testing for managing potential health risks, which expands the number of ways to utilize respiratory disease diagnostic testing. Therefore, the awareness of respiratory disease diagnostics has improved greatly and the commitment by the health care community to be prepared for future outbreaks has moved respiratory disease diagnostics from solely reactive tools to a major component of the overall resilience of the health care community. This shift toward proactive monitoring, rapid testing, and scalable diagnostic infrastructure is driving sustained growth and innovation across the respiratory diagnostics market.

Growth strategies adopted by players to establish their foothold in the market

Players operating in this market are adopting various growth strategies such as new product launches, partnerships and collaborations, and mergers and acquisitions to garner market share. For instance,

• In July 2025, PHASE Scientific expanded its INDICAID respiratory portfolio through the exclusive US launch of FebriDx, a rapid point-of-care test that differentiates bacterial from non-bacterial respiratory infections in about 10 minutes. The FDA-cleared test strengthens PHASE Scientific’s leadership in point-of-care respiratory diagnostics by enabling improved antibiotic stewardship and addressing antimicrobial resistance across urgent and outpatient care settings
• In May 2025, Vitalograph and Thorasys announced a strategic partnership at the ATS Annual Conference, marking the U.S. launch of the tremoflo C2 portable oscillometer. The collaboration integrates oscillometry into Vitalograph’s respiratory diagnostics portfolio, expanding access to effort-free, advanced lung function testing for broader patient populations
• In September 2024, Roche launched the cobas Respiratory flex test, the first diagnostic to use its proprietary TAGS technology, enabling high-throughput, simultaneous detection of up to 12 respiratory viruses from a single patient sample. The innovation expands syndromic multiplex PCR testing on existing cobas 5800/6800/8800 systems, improving diagnostic speed, flexibility, and laboratory efficiency while strengthening outbreak preparedness
• In September 2024, Vitalograph acquired its long-standing partner Morgan Scientific to expand its global respiratory diagnostics business and strengthen its US commercial presence. The acquisition integrates Morgan Scientific’s ComPAS2 pulmonary function testing software with Vitalograph’s VitaloPFT systems, enhancing advanced lung function assessment and innovation

To learn more about this report, download the PDF brochure

Product and Service Segment Outlook

The largest segment of the market for diagnostics is made up of instruments and devices. This is primarily due to the growing number of Pulmonary Function Tests (PFTs), as well as imaging devices (CT, MR, US and Fluoroscopy) being used in hospitals and diagnostic laboratories, as well as the increasing use of POC devices. The high unit price, long replacement cycles and essential functions of instruments during both routine and advanced respiratory assessments all contribute to the total revenue generated from the sale of these products. In contrast, services & software is the fastest growing segment of the respiratory diagnostics market due to an overall trend towards the digitization of diagnostics, increased demand for data analysis, remote patient monitoring, and the increasing use of artificial intelligence (AI) to interpret information, as well as increases in cloud based applications that enhance workflow, improve integration between systems and create better tools for longitudinal care of patients with respiratory diseases across different types of healthcare settings.

Regional Outlook: North America expected to hold a major share in the respiratory diagnostics market

North America currently holds the largest share of the respiratory diagnostics market, mainly because of high burden of asthma and COPD, early adoption of advanced diagnostic technologies, and strong reimbursement support. In contrast, the Asia–Pacific region is expanding the fastest which is attributed to the driven by worsening air quality, smoking prevalence, expanding healthcare infrastructure, and increased screening initiatives. Europe is supported by an aging population, stringent clinical guidelines, and widespread use of pulmonary function testing in routine care, while, in Latin America and the Middle East & Africa, growth is supported by improving access to diagnostics, rising disease awareness, and gradual investments in healthcare capacity.

Competitive Landscape Analysis

The global respiratory diagnostics market is marked by the presence of established and emerging market players such as Thermo Fisher Scientific Inc. (US); Abbott (US); Koninklijke Philips N.V. (The Netherlands); Becton, Dickinson and Company (BD) (US); Bio-Rad Laboratories, Inc. (US); BIOMÉRIEUX (France); Siemens Healthineers AG (Germany); Seegene Inc. (S. Korea); Nihon Kohden Corporation (Japan); and ResMed Inc. (US); among others. Some of the key strategies adopted by market players include product launches, partnerships and collaborations, and mergers and acquisitions, and geographic expansion.

Get a sample report for competitive landscape analysis

Report Scope

Global Respiratory Diagnostics Market Segmentation

This report by Medi-Tech Insights provides the size of the global respiratory diagnostics market at the regional- and country-level from 2024 to 2031. The report further segments the market based on product & service, test type, indication, diagnosis type, and end user.

Market Size & Forecast (2024-2031), By Product & Service, USD Billion

• Instruments & Devices
• Assays & Reagents
• Services & Software

Market Size & Forecast (2024-2031), By Test Type, USD Billion

• Mechanical Tests
• Imaging Tests
• Traditional Diagnostic Tests
• Molecular Diagnostic Tests

Market Size & Forecast (2024-2031), By Indication, USD Billion

• Chronic Obstructive Pulmonary Disease (COPD)
• Asthma
• Tuberculosis
• Lung Cancer
• Other Indications

Market Size & Forecast (2024-2031), By Diagnosis Type, USD Billion

• Syndromic Diagnosis
• Etiological Diagnosis
• Prognosis Diagnosis

Market Size & Forecast (2024-2031), By End User, USD Billion

• Hospitals & Clinics
• Diagnostic Laboratories
• Other End Users

Market Size & Forecast (2024-2031), By Region, USD Billion

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Related Reports

Respiratory Care Devices Market (2026-2031) Size, Share, Analysis By Product (Respiratory Care Monitoring Devices, Diagnostics Respiratory Care Devices, Consumables and Accessories), Disease (Sleep Apnea, Asthma, Infectious Diseases), Region and Segment Forecast

Global Neonatal Intensive Care Respiratory Devices Market Size & Trends Report Segmented by Device Type (Nebulizers, Inhalers, Ventilators, Apnea Monitors), End-user (Hospitals, Specialty Clinics, Nursing Homes) & Regional Forecast to 2030

Global Cough Assisted Devices Market Size & Trends Report Segmented by Product Type (Automatic, Manual), Choice of Delivery (Mouthpiece, Face Mask, Adapter), End-user (Hospitals, Home-care Settings) Industry Analysis & Regional Forecast to 2030